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Abstract
Background: Lysine specific demethylase 1 (LSD1) has been identified and biochemically characterized in epigenetics, but
the pathological roles of its dysfunction in lung cancer remain to be elucidated. The aim of this study was to evaluate the
prognostic significance of LSD1 expression in patients with non-small cell lung cancer (NSCLC) and to define its exact role in
lung cancer proliferation, migration and invasion.
Methods: The protein levels of LSD1 in surgically resected samples from NSCLC patients were detected by
immunohistochemistry or Western blotting. The mRNA levels of LSD1 were detected by qRT-PCR. The correlation of
LSD1 expression with clinical characteristics and prognosis was determined by statistical analysis. Cell proliferation rate was
assessed by MTS assay and immunofluorescence. Cell migration and invasion were detected by scratch test, matrigel assay
and transwell invasion assay.
Results: LSD1 expression was higher in lung cancer tissue more than in normal lung tissue. Our results showed that over-
expression of LSD1 protein were associated with shorter overall survival of NSCLC patients. LSD1 was localized mainly to the
cancer cell nucleus. Interruption of LSD1 using siRNA or a chemical inhibitor, pargyline, suppressed proliferation, migration
and invasion of A549, H460 and 293T cells. Meanwhile, over-expression of LSD1 enhanced cell growth. Finally, LSD1 was
shown to regulate epithelial-to-mesenchymal transition in lung cancer cells.
Conclusions: Over-expression of LSD1 was associated with poor prognosis in NSCLC, and promoted tumor cell proliferation,
migration and invasion. These results suggest that LSD1 is a tumor-promoting factor with promising therapeutic potential
for NSCLC.
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Introduction
Lung cancer is one of the leading causes of cancer death
worldwide. Non-small cell lung cancer (NSCLC) is the most
common type of lung cancer [1]. The 5-year survival rate for lung
cancer remains poor. In order to develop more effective therapies,
it is important to obtain a better understanding of the molecular
biology of lung cancer.
Genetic alterations are a hallmark of human cancer. In recent
years, the cancer genomics field has made significant advances in
identifying genetic lesions in cancer. Furthermore, the importance
of epigenetic changes that occur during lung cancer development
has also been recognized [2]. Epigenetic changes are associated
with both DNA methylation and histone modifications [3].
Histone modifications, such as acetylation, phosphorylation and
methylation, are the switches that alter chromatin structure to
allow posttranscriptional activation or repression of downstream
proteins [4]. Understanding these epigenetic changes will identify
novel cancer-related genes that may represent attractive targets for
cancer treatment and provide new insights into the biology of lung
cancers. Thus, an integrative approach in lung cancer research,
combining epidemiological, genetic and epigenetic information,
has emerged as an important concept for cancer therapy [5].
The methylation status of histone methyltransferases and
histone demethylases plays a pivotal role in the regulation of gene
expression [6]. Histone demethylase lysine specific demethylase 1
(LSD1), the first histone demethylase that was discovered as
a nuclear homolog of amine oxidases, removes the methyl groups
from mono- and dimethylated Lysine (Lys)4 of histone H3
(H3K4me1/2) and Lys9 of histone H3 (H3K9me1/2) [7]. LSD1
is essential for mammalian development and involved in many
biological processes, such as cell-type differentiation and gene
activation and repression [8]. A recent study indicated that LSD1
might promote cell phase transition (deficiency in LSD1 led to
partial cell cycle arrest in G2/M) and cell proliferation, suggesting
that its over-expression might promote tumorigenesis [9]. The
expression of LSD1 has been associated with tumor recurrence
during therapy in various cancers, further implicating LSD-1 as
a tumor promoter [10–12]. Tissue cDNA microarray analysis also
revealed LSD1 transactivation in lung and colorectal carcinomas
[11]. Knocking down of LSD1 with small interfering (si)RNAs
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cancer cell lines [11]. However, although these studies demon-
strated that LSD1 may be associated with the pathogenesis of lung
cancer, the expression and significance of LSD1 in NSCLC is
obscure.
In this study, we attempted to investigate the expression and
function of LSD1 in NSCLC, its relationship with clinicopatho-
logical features, and its prognostic value for survival of patients
with NSCLC. Finally, we also aimed to determine the exact role of
LSD1 in lung cancer proliferation, migration and invasion.
Materials and Methods
Patients and Specimens
Surgical specimens from 80 NSCLC patients obtained at the
Nanjing Chest Hospital and the Jinling Hospital from January
2001 to December 2003 were retrospectively collected for study.
These consisted of 38 squamous carcinomas and 42 adenocarci-
nomas, along with patient-matched adjacent non-tumor tissue
specimens. None of the patients had received radiotherapy or
chemotherapy prior to surgery. All patients had been followed-up
for five years after operation, and complete clinical data were
electronically recorded. All tumor tissues were classified according
to the World Health Organization classification guidelines. The
staging of the tumors followed the 7
th Union International
Classification at Cancer criteria defined in 2009. This study was
approved by the Ethical Committee of the Jinling Hospital at
Nanjing. All samples were anonymized, and none of the
researchers conducting the experiments had access to the
clinicopathological data.
Immunohistochemical (IHC) Staining
All samples were fixed in 10% formalin, embedded in paraffin,
sectioned consecutively at 5 mm, and stained by hematoxylin and
eosin.Thesectionsweredeparaffinizedandrehydratedaccordingto
routineprotocol.Thesectionswereincubatedforovernightwiththe
specific primary LSD1 antibodies (1:100 dilution; Cell Signaling,
Danvers,MA,USA).Theslideswereincubatedfor30minwithgoat
anti-rabbit immunoglobulins (E0432; Cell Signaling) after being
washed with Tris-buffered NaCl solution. The slides were then
incubated for 30 min with stripped AB complex/AP (K0391; Dako,
Peking, China). Counterstaining was performed with hematoxylin.
Thepercentageofpositivecellswasdeterminedbycounting500cells
infiverandomareaspersection.Nuclearimmunostainingresultsfor
LSD1 were evaluated using a semi-quantitative Remmele scoring
system [13], which calculated the staining intensity and the
percentage of positive cells. IHC staining was scored according to
thefollowingcriteria:–,noneofthecellsstained;+,1–40%ofthecells
stained; ++; 40–70% of the cells stained; +++, 70–100% of the cells
stained. IHC score of LSD1 expression was [0 (negative) # score ,
2+] and [2+ # score #3+], which represented low and high
expression, respectively.
Western Blotting
The lung cancer tumor tissues and adjacent non-tumor tissues
were homogenized. Total proteins (30 mg) from clinical specimens
or cell cultures were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, followed by electrotransfer to
a nitrocellulose membrane by use of a transfer cell (Bio-Rad,
Hercules, CA, USA). Western blotting was carried out by
sequential incubation in 5% non–fat milk blocking buffer at room
temperature for 60 min, followed by primary antibody against
either LSD1 (1:500; Cell Signaling), AcH3K9, Twist1, E-cadherin,
N-cadherin or b-actin at 4uC overnight, and finally horseradish
peroxidase-conjugated anti-rabbit secondary antibody (1:5000) at
room temperature for 90 min. Immunoreactive bands were
detected by reaction with the ECL detection system reagents
(Amersham, Arlington Heights, IL, USA) and exposure to X-ray
film, which was the developed and photographed.
mRNA Extraction and Quantitative Reverse Transcription
(qRT)-PCR
Tissues were homogenized and total cellular mRNA was
isolated using the TRIzol reagent (Invitrogen, Carlsbad, CA,
USA). The cDNA was transcribed using M-MLV reverse
transcriptase (Promega, Madison, WI, USA), according to the
manufacturer’s protocol. qRT-PCR was performed using the
FastStart Universal SYBR Green Master Mix kit (Roche, San
Francisco, CA, USA). Relative mRNA levels of LSD1 were
normalized to levels of the housekeeping gene GAPDH and
calculated by the 2-DDCt method. The following primers were
used: GAPDH, forward: 5’-CCATGTTCGTCATGGGTGT-
GAACCA-3’ and reverse: 5’-GCCAGTAGAGGCAGGGAT-
GATGTTG-3’; LSD1, forward: 5’-GAAACTGGAATAGCAGA-
GAC-3’ and reverse: 5’-GGTGGACAAAGCACAGTATCA-3’.
Cell Culture, Transfection and Treatment
A549, H460, and 293T cells were obtained from the American
Type Culture Collection (Manassas, VA, USA) and cultured in
RPMI medium supplemented with 10% fetal bovine serum (FBS),
2 mM L-glutamine and 100 mg/mL penicillin/streptomycin. The
plasmid Flag-LSD1 (3ug); kindly provided by Dr. Yang Shi,
University of Southern California, Los Angeles, CA, USA), over-
expression plasmid LSD1 (3 mg) and LSD1 siRNA (3 mg) were
transfected into A549 and H460 cell lines in 6-well plates (1 mg/
mL) using the Lipofectamine reagent (Invitrogen), according to the
manufacturer’s instructions. Pargyline (Sigma-Aldrich, St. Louis,
MO, USA), a monoamine oxidase inhibitor, was used to
chemically block LSD1-mediated demethylation [14]. Cells were
treated with pargyline for 48 h, and then were subjected to MTS
assay. The data are presented as fold-changes in relative light
units/milliunits of pargyline, and represent the average of three
independent experiments.
Cell Proliferation, Growth, MTS Assays
For cell growth assay, 50,000 cells/well were seeded in triplicate
in a 24-well plate with complete growth medium. Cells were
counted over six days using a hemocytometer. For the MTS assay
(Promega), 500 cells/well were seeded in triplicate in a 96-well
plate for each cell line. At 12, 24, and 48 h, 20 mL of MTS reagent
was added to each well, incubated for 1 h at 37uC, and the results
were analyzed by a plate reader at 490 nm. The sample data was
normalized to background readings of media only.
Three-dimensional Cell Culture, Collagen Invasion Assay,
and Scratch Assay
Three-dimensional basement membrane cultures were estab-
lished as previously described [15]. Briefly, 5000 cells/well were
grown in 2% matrigel (BD Biosciences, San Jose, CA, USA) with
epidermal growth factor (EGF) on a 50% matrigel base layer. The
collagen invasion assay was performed as previously described
[16]. Briefly, 5000 cells/well were seeded in 2% matrigel on a layer
of 1:1 collagen (BD Bioscience) to matrigel mix. Culture growth
was recorded on day 5. For the scratch assay, cells were grown in
complete growth medium until 90–100% confluency was reached.
A 3 mm wound was introduced across the diameter of each plate.
Cell migration was observed by microscopy at 24 and 48 h later.
LSD1 in NSCLC
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Student’s t-test and ANOVA were used to investigate the
associations between LSD1 expression and clinical factors (age,
sex, smoking, tumor stage, histology, tumor size, nodal status,
and overall survival). Pearson’s correlation analysis was used to
evaluate the degree of linear correlation between two variables.
Kaplan-Meier survival analysis was performed to determine the
prognostic value of LSD1, and log-rank test was used to compare
Figure 1. LSD1 expression and distribution in NSCLC tumor tissues and normal lung tissues, detected by IHC staining. (A, B) LSD1
expression was up-regulated in lung squamous cancer tissue. The arrows indicate LSD1-positive cancer cells, which were located in the cell nuclei.
Magnification: A,620; B,660. (C, D) LSD1 expression was up-regulated in lung adenocarcinoma cancer tissue. Magnification: C,620; D,660. (E, F) IHC
revealed that LSD1 expression was weak in normal lung tissues. Magnification: E,620; F,660. IHC scores of LSD1 expression were: low, [0 (negative)
# score , 2+]; high, [2+ # score #3+]. P,0.05 indicated statistically significant differences between groups.
doi:10.1371/journal.pone.0035065.g001
Figure 2. Up-regulation of LSD1 expression in NSCLC tumor tissues. (A) The protein level of LSD1 in lung cancer tissue was significantly
higher than in normal tissue (P,0.01), as detected by Western blot. b-tubulin was used as a loading control. (B) Sample 122, 206 and 207 are shown
as representatives of the three groups: N, normal lung tissues: C, NSCLC tissues; P, paracarcinoma tissues. (C) The mRNA level of LSD1 was detected
by qRT-PCR, and the mRNA expression of LSD1 was significantly higher in tumor tissue than in normal tissue (P,0.05).
doi:10.1371/journal.pone.0035065.g002
LSD1 in NSCLC
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considered statistically significant and P,0.01 was considered
highly significant. All statistical analyses were performed using
the SPSS program v17.0 for Windows (SPSS, Chicago, IL,
USA).
Results
LSD1 Expression was Up-regulated in NSCLC Tumor
Tissues
We first examined expression levels of LSD1 in 80 NSCLC
tumor tissues and 20 normal lung tissues by IHC staining. High
LSD1 expression was detected in the nuclei of malignant cells,
while weak staining was observed throughout the non-neoplastic
tissues (Fig. 1). Specifically, the expression of LSD1 was observed
in 90.0% of lung carcinomas (72/80) and 10.0% of benign lung
specimens (2/20). High levels of LSD1 expression (score: ++-+++)
were detected in 37 (46.3%) tumor tissues from NSCLC patients.
We next examined LSD1 expression in 40 randomly selected
NSCLC tumor tissues, paracarcinoma lung tissues, and normal
lung tissues by Western blotting. The results revealed a statistically
significant elevation of LSD1 expression in tumors, as compared to
the normal lung tissues using b-tubulin as the reference (two-tailed
paired t-test, n=40, P,0.01) (Fig. 2A). The protein level of LSD1
in samples 122, 206, and 207 is shown in Figure 2B.
To further validate the above protein results, we also examined
the mRNA levels of LSD1 in these 40 selected NSCLC tumor
tissues and normal lung tissues by qRT-PCR using GAPDH as
reference. We found that the mRNA level of LSD1 in cancer
tissues (Ct=19.961.01) was significantly higher than that in
normal lung tissues (Ct=22.160.9) (two-tailed paired t-test,
n=40, P,0.05) (Fig. 2C).
LSD1 Expression was Associated with Overall Survival
To evaluate the clinical significance of LSD1 over-expression in
lung cancer, we analyzed whether expression levels of LSD1 were
associated with overall survival in NSCLC. As shown Table 1,
high protein levels of LSD1 were significantly associated with
survival (x
2=12.87, P=0.0003), but not correlated with any of the
clinicopathologic characteristics (including age, smoking habits,
sex, tumor diameter, histologic type, visceral pleural invasion,
pathologic stage, or type of operation; all, P.0.05). During the 5-
year follow-up period, 52 out of 80 (65%) NSCLC patients died as
a result of disease progression. Kaplan–Meier curves indicated
that patients with increased LSD1 expression (28 cases) had
a significantly shorter overall survival than those with decreased
LSD1 expression (52 cases) (P=0.0003) (Fig. 3A).
In agreement with this, we also determined that higher mRNA
expression of LSD1 was associated with decreased overall survival
in NSCLC patients (P,0.05) (Fig. 3B.).
Table 1. Statistical analysis of LSD1 expression levels in
clinical lung tissues.
LSD1
Factor Cases, n Negative Low High x
2 P
Age, years 80 10 43 27 0.007 0.934
,60 38 3 22 13
$60 42 7 21 14
Gender 0.553 0.460
Male 61 10 31 20
Female 19 0 11 8
Smoker 0.760 0.180
No 41 2 21 17
Yes 39 8 20 11
Histology 0.007 0.934
Squamous
carcinoma
38 6 19 13
Adenocarcinoma 42 7 21 14
Pathological
stage
0.030 0.870
T,3cm 18 1 11 6
T$3cm 62 9 31 22
Nodal status 0.005 0.940
N0 49 6 26 17
N1-2 31 4 16 11
OS, months 12.870 0.0003
#12 14 2 6 6
12–36 27 3 8 16
36–60 11 2 5 4
.60 28 2 24 2
doi:10.1371/journal.pone.0035065.t001
Figure 3. LSD1 expression was associated with overall survival in NSCLC. Blue lines depict high levels of LSD1 expression, and red lines
depict low levels of LSD1 expression in NSCLC samples. (A) NSCLC patients with lower LSD1 protein levels had better prognosis. (unadjusted P-
value=0.0003; low expression cases, n=52 and high expression cases, n=28). (B) Patients with lower mRNA levels of LSD1 also had longer survival
(P,0.05).
doi:10.1371/journal.pone.0035065.g003
LSD1 in NSCLC
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The expression of LSD1 was lower in the A549 cell than in the
H460 cell line, as shown in Figure 4. Therefore, the Flag-LSD1
plasmid was transfected into the A549 cells and the LSD1 siRNA
plasmid was transfected into the H460 cells. The 293T normal
epithelial cells were used as a negative control.
We detected the OD value of A549, H460 and 293T cells by
MTS to generate cell growth curves. In all three cell lines, the
cellular proliferation declined along with pargyline treatment in
a concentration-dependent manner. It was notably lower in the
4 mM-treated group than in the 1 mM- or 2 mM-treated groups.
In addition, it was also lower in the 1 mM-treated group than in
the 3 mM-treated group; however, there was no difference
between the 1 mM- and 2 mM-treated groups or the 3 mM-
and 4 mM-treated groups (P.0.05), as shown in Figure 5A-C.
The proliferation significantly increased in the A549 group after
transfection of the Flag-LSD1 plasmid (P,0.05); however, it
significantly decreased in the H460 group after transfection of the
LSD1 siRNA plasmid (P,0.05). The pCMV plasmid was used as
the control in the A549 transfection group, and the LSD1 siRNA
control plasmid was used in the H460 cell transfection group
(Fig. 5D).
We further identified the role of LSD1 in A549 and H460 cell
proliferation by immunofluorescence staining. The change in
number of proliferating cells was observed by BrdU staining. The
results demonstrated that the cell proliferation was significantly
Figure 4. Expression of LSD1 in A549, H460 and 293T cells. The
expression of LSD1 in the A549 and H460 lung cancer cells was higher
than in the 293T cells. The protein level in the H460 cell line was higher
than that in the A549 cell line. b-actin was used as loading control.
doi:10.1371/journal.pone.0035065.g004
Figure 5. The proliferation curve of A549, H460 and 293T cell lines after pargyline treatment and transfection of Flag-LSD1 or LSD1
siRNA. The series of curves represent cell proliferation at 0 h to 48 h after exposure to different concentrations of pargyline treatment and
transfection with the different plasmids. (A) The LSD1 inhibitor, pargyline (from top to bottom: 1mM, 2mM, 3mM and 4mM), and LSD1 siRNA
inhibited proliferation of the A549 cell line. The A549 cell proliferation was significantly decreased in the different groups, as compared to the
controls (*P,0.05). (B) Pargyline inhibited H460 cell line survival. Moreover, a stronger inhibitory effect was observed in the H460 cell line, but there
were no significant differences between the two cell lines. The H460 cell proliferation was significantly decreased in the different concentration
groups, as compared to the controls (*P,0.05). (C) Pargyline inhibited the survival of the 293T cell line. (D) The proliferation curve after transfection of
Flag-LSD1 plasmid into the A549 cell and transfection of LSD1 siRNA plasmid into the H460 cell. In A549 cells, the proliferation was significantly
higher after transfection of the Flag-LSD1 plasmid, as compared to the pCMV5-transfected control (*P,0.05). In H460 cells, the proliferation was
significantly lower after transfection of LSD1 the siRNA plasmid, as compared to the cells transfected with siRNA control plasmid (*P,0.05).
doi:10.1371/journal.pone.0035065.g005
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into the A549 cell line. Meanwhile, cell proliferation decreased in
the H460 cells transfected with the LSD1 siRNA plasmid. It
decreased in both cell lines after pargyline treatment, as shown by
immunofluorescence staining (Fig. 6), which also confirmed that
LSD1 is involved in tumor cell proliferation.
LSD1 Promoted the Migration of Lung Cancer Cells
Cell migration was investigated by the cell scratch assay.
Compared with the control group, the number and rate of
migrated cells was gradually reduced after transfection with LSD1
siRNA plasmid in the H460 cell lines. The migrating cells reached
a peak at 48 h, as shown in Figure 7A. In contrast, the number of
migrated cells were significantly increased in the A549 cell line
after transfection with Flag-LSD1 plasmid, as compared to the
control group (P,0.05). The relative speed of migration is shown
in Figure 7B.
The Role of LSD1 in Lung Cancer Invasion
The ability of cells to cross matrigel indicated the invasiveness of
the A549 and H460 cell lines. H460 cells transfected with LSD1
siRNA plasmid were less invasive than the control group (P,0.05).
A549 cells transfected with Flag-LSD1 plasmid were more invasive
Figure 6. Changes in LSD1 activity affect cell proliferation in the A549 and H460 cell lines, as detected by immunofluorescence.
Images are shown at 620 magnification. Green, red and blue fluorescence represent LSD1, BrdU and Topro-3, respectively. The proliferation
significantly increased in the A549 cells after transfection of the Flag-LSD1 plasmid. However, proliferation decreased in the H460 cells after
transfection of the LSD1 siRNA plasmid. Pargyline treatment reduced proliferation in both cell lines. Topro-3 staining shows nuclear localization, and
BrdU staining shows the proliferating cells.
doi:10.1371/journal.pone.0035065.g006
Figure 7. The relative velocity change of cell migration in A549 and H460 cells transfected with Flag-LSD1 or LSD1 siRNA plasmid,
respectively. The migration velocity gradually decreased from 6 h to 48 h after transfection of the LSD1 siRNA plasmid in the H460 cells, which was
significantly different from the velocity at 24 h and 48 h (*P,0.05). The migration rate gradually increased after transfection of Flag-LSD1 plasmid
into the A549 cells, which was significantly different from the velocity at 24 h and 48 h (*P,0.05). All transfection groups were significant different
from the control groups (*P,0.05).
doi:10.1371/journal.pone.0035065.g007
LSD1 in NSCLC
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P,0.05). The amount of invading cells crossing through the
matrigel basement membrane is shown in Figure 8.
LSD1 Regulated Epithelial-to-mesenchymal Transition
(EMT) in Lung Cancer Cells
To investigate whether LSD1 regulates the EMT transition in
lung cancer cells, we examined the expression of the key EMT
transcriptional repressor TWIST1 and the EMT markers E-
cadherin and N-cadherin in LSD1-over-expressing A549 cells
(transfected with the Flag-LSD1 LSD1 over-expressing plasmid)
and LSD1 knocked down H460 cells (transfected with the LSD1
siRNA plasmid, or treated with 4 mM pargyline). The effects on
H3K9, AcH3K9, Twist1, E-cadherin and N-cadherin expression
induced by alteration of the LSD1 activity were examined. While
expression of total H3K9 was unaffected, LSD1 over-expression
led to decreases in H3K9 acetylation and E-cadherin expression
and increases in Twist1 and N-cadherin expression. Meanwhile,
H3K9 acetylation levels and E-cadherin expression were increased
in LSD1 knock down cells, suggesting that LSD1 expression might
be correlated with AcH3K9, Twist1, E-cadherin and N-cadherin
expression, as shown in Figure 9.
Discussion
In recent years, epigenetics has become a hot topic in cancer
research. The balance of methylation and demethylation in
epigenetic modification affects gene expression and cellular
activity. Studies have demonstrated that aberrant histone lysine
methylation in cancer is associated not only with the repression of
chromatin related to specific genes, but also with the repression of
large chromosomal regions. Epigenetic changes in LSD1 have
been shown to play a key role in carcinogenesis [17]. LSD1 can
prevent the accumulation of the dimethyl groups of p53,
repressing p53-mediated transcriptional up-regulation, preventing
apoptosis, and contributing to human carcinogenesis via a chro-
matin modification mechanism.
To date, only a few studies have implicated LSD1 in NSCLC.
Hayami et al. demonstrated that LSD1-specific siRNAs signifi-
cantly knocked down LSD1 expression and resulted in suppressed
proliferation of various lung cancer cells [11]. However, the
association between LSD1 and the survival of NSCLC patients
was not well defined, and the role of LSD1 in proliferation,
migration and invasion in NSCLC was obscure. Our study
investigated the associations of LSD1 expression and clinical
features of NSCLC patients diagnosed as stage I/II. In order to
demonstrate that the epigenetic changes were associated with
genetic changes in lung cancer, we first investigated the expression
of LSD1 in NSCLC clinical samples.
Previous studies demonstrated that LSD1 protein and mRNA
levels could act as biomarkers for patients with more aggressive
tumors of breast cancer, prostate cancer, and neuroblastoma [18–
20]. In our study, we detected LSD1 by IHC analysis, Western
blotting, and qRT-PCR. A strong point of this research is the
finding that expression of LSD1 was significantly correlated with
overall survival of NSCLC patients. Our current research
investigated the role of LSD1 in NSCLC. Further studies on
LSD1 in other tumor types may reveal that patients with higher
levels of LSD1 (regardless of mRNA or protein and/or regardless
of primary tumor type) have poorer survival than patients with
lower levels of LSD1.
We further demonstrated that LSD1 was important for cancer
cell proliferation and invasion. LSD1-induced activation of
proliferation, migration and invasion in tumor cell was inhibited
by pargyline. Down-regulation of LSD1 expression by siRNA in
tumor cell lines led to increased cell growth, migration and
invasion. These data suggest that LSD1 may influence the
transformation of tumor cells and may also promote EMT in
the lung epithelium. Further research needs to be conducted in
order to determine whether over-expression of LSD1 is an early or
late event in lung tumorigenesis and what the mechanism of over-
expression is. We have presented data suggesting that LSD1 is up-
regulated in the lung cancer tumor promotion pathway and that it
acts to increase cell growth, migration and invasion, and to restore
a transformed epithelial phenotype. Pharmacological suppression
of LSD1 may represent a promising approach for NSCLC
treatment.
Figure 8. The numbers of A549 and H460 cells that transversed
the matrigel basement membrane. The transversed cell amount
was significantly higher for A549 cells transfected with the Flag-LSD1
plasmid; however, transfection of LSD1 siRNA plasmid into the H460
cells led to decreased amounts of invasive cells. The numbers of
invasive cells from both transfection groups were significant different
from the control group (* P,0.05).
doi:10.1371/journal.pone.0035065.g008
Figure 9. Changes in LSD1 activity affect AcH3K9, Twist1, E-
cadherin and N-cadherin expression in A549 and H460 cells.
The expression of total H3K9 did not change remarkably. When LSD1
activity was up-regulated, Twist1 and N-cadherin expression increased
and AcH3K9 and E-cadherin expression decreased. When LSD1 activity
was down-regulated, Twist1 and N-cadherin expression decreased and
AcH3K9 and E-cadherin expression increased. The Flag-LSD1 plasmid
was transfected into the A549 cell line, and the LSD1 siRNA plasmid was
transfected into the H460 cell line. b-actin was used as loading control.
doi:10.1371/journal.pone.0035065.g009
LSD1 in NSCLC
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regulatory network of LSD1. Transcriptional analysis revealed
that the LSD1/NuRD complexes regulate several cellular
signaling pathways [21], including the TGFb1 signaling pathway
that is critically involved in cell proliferation, survival, and
epithelial-to-mesenchymal transition. We demonstrated that
LSD1 promoted the invasion and metastatic potential of lung
cancer cells in vitro. We also found that LSD1 is up-regulated in
lung carcinomas and that its level of expression is negatively
correlated with that of AcH3K9, Twist1 and N-cadherin, and
positively correlated with that of E-cadherin. Our data provide
a molecular basis for the interplay of histone deacetylation in
chromatin remodeling, indicating that LSD1 may affect the EMT
and acetylation of H3K9.
The aberrant over-expression of LSD1 in lung cancer may
make it a good candidate as a therapeutic molecular target [11].
This kind of information also indicates that we should carry on the
development of novel anticancer therapy based on epigenetic
status. As it has implications for the discovery of epigenetic
markers, an important question to resolve is how to define
potential targets for epigenetic therapy. First-generation drugs
targeting the relatively promiscuous DNA methylation and histone
acetylation modifiers have had success in the treatment of
hematological cancers [22]. If LSD1 inhibition leads to significant
de-repression of some genes, LSD1 might be an important
alternative target for therapy. Epigenetic control of gene
regulation is a rapidly developing field with substantial potential,
and oncology is likely to be the therapeutic application in which
the fastest progress is made. To date, synthetic inhibitors of
classical histone deacetylases have been widely used as biological
tools for epigenetic studies, and some have advanced to clinical
studies. In addition, development of histone methyltransferase and
demethylase inhibitors has recently been reported [21,23]. In lung
cancer, over-expression of LSD1 should contribute to gene
repression to inhibit cellular growth and malignant progression,
but where there is an actual purpose of LSD1 remains unknown.
We plan to investigate this in future studies.
In conclusion, we found that LSD1 was over-expressed in
NSCLC patients, through early to late stages of carcinogenesis.
LSD1 is present in the nucleus and promotes proliferation,
possibly through regulation of a wide variety of chromatin
functions. Meanwhile, over-expression of LSD1 promoted tumor
cell proliferation, migration and invasion. Further validation with
functional analyses of this protein in the context of human
carcinogenesis may assist in development of novel therapeutic
strategies for lung cancer.
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